Vertex has partnered its oncology agent VX-944 in a deal worth up to US$73 M. While Vertex's choice of the relatively small company Avalon as its most recent licensing partner is suprising in some respects, Avalon's technology and cancer focus are a good match for VX-944, and Vertex clearly believes it has a committed partner to progress the compound quickly to proof-of-concept.